Why the study?
To determine whether Si-Miao-Yong-An Decoction (SMYAD) could ameliorate pressure overload-induced heart hypertrophy and to explore its mechanisms.
Does Si-Miao-Yong-An Decoction improve cardiac hypertrophy and dysfunction in mice with pressure overload?
Does Si-Miao-Yong-An Decoction improve cardiac hypertrophy and dysfunction in mice with pressure overload?
Si-Miao-Yong-An Decoction protects against pressure overload-induced cardiac hypertrophy and dysfunction in mice, potentially by inhibiting platelet aggregation and activation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in murine hypertrophy models; leaves open translation to human pressure-overload therapies.
Objective The aim of this study was to determine whether SMYAD could ameliorate pressure overload-induced heart hypertrophy and its mechanisms. Methods C57BL/6 mice were subjected to either sham or transverse aortic constriction (TAC) surgery to induce heart hypertrophy. SMYAD (14.85g/kg/d, po) or Captopril (16.5mg/kg/d, po) was administered to the mice for 4 weeks. Cardiac function was evaluated based on echocardiography. Histological and biochemical examination were also performed by HE staining. Protein expression of CD41, CD61, P-selectin were measured with western blotting and immunohistochemistry. Results Four weeks after transverse aortic constriction, mice developed exaggerated cardiac hypertrophy and demonstrated a strong decrease in left ventricular ejection fraction (LVEF) compared with sham (29.9±9.3% versus 66.0±9.9%; P<0.001). Conversely, SMYAD improved cardiac dysfunction with a preserved LVEF (66.5±17.2%; P<0.001). The same changes were observed in left ventricular posterior wall, left ventricular volume and left ventricular internal diameter. The ratio of heart weight to body weight was also significantly increased 4 weeks after TAC, which could be rescued by SMYAD. Furthermore, western blot and immunohistochemistry indicated that the protein expressions of platelet aggregation marker (CD41, CD61) and platelet activation marker (P-selectin) were significantly higher compared to control. These pathological alterations in TAC-mice were significantly ameliorated or blocked by SMYAD administration. Conclusions Our results suggested that SMYAD exerted its effect by inhibiting platelet aggregation and activation as revealed by CD41/CD61/P-selectin up-regulation. Activation of the platelet might contribute to the therapeutic effects of SMYAD in failing heart.
No takes yet. Share an insight, caveat, or question.
Su et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: